TENX

Over the past six months, Tenax hosted a virtual call with key opinion leaders to discuss the treatment landscape for PH-HFpEF and its Phase 3 TNX-103 program. The company announced the result of a prespecified blinded sample size assessment for the LEVEL study and participated in healthcare conferences. The U.S. Patent and Trademark Office issued a Notice of Allowance for a patent expanding protection for subcutaneous levosimendan. Tenax Therapeutics reported its Fourth Quarter and Full Year 2025 Financial Results and provided a corporate update, which included achieving its randomization target of 230 patients in the Phase 3 LEVEL study, leading to a stock surge. The company announced inducement grants under Nasdaq Listing Rule 5635(c)(4) and the appointment of Timothy Healey as Chief Commercial Officer and Thomas R. Staab, II as Chief Financial Officer.